ZFIN ID: ZDB-FISH-150901-14790
Fish name: f2Tg
Genotype: f2Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by f2Tg
No data available
GENE EXPRESSION
Gene expression in f2Tg
Protein expression
Antibody Antigen Genes Structure Conditions Figures
zn-5 standard conditions Fig. 1Fig. 2Fig. 3Fig. 4Fig. 5Fig. 6 from Andersen et al., 2015
Ab-S46 chemical treatment: 4-(diethylamino)benzaldehyde Fig. 5 with image from Rydeen et al., 2016
Fig. 1 with image from Waxman et al., 2008
Ab2-fn control Fig. 3 with image from Sallin et al., 2016
Ab-MF20 standard conditions Fig. 6 with image from Colombo et al., 2017
Fig. 4 with image from George et al., 2015
Ab1-N2.261 control Fig. 3 with image from Sallin et al., 2016
Ab1-mef2 surgical manipulation: pericardial cavity Fig. 1 with image from de Preux Charles et al., 2016
Ab1-mef2 control Fig. 1 with image from de Preux Charles et al., 2016
Ab1-igf1r control Fig. 6 with image from Sallin et al., 2016
Ab1-mcm5 control Fig. 1 with imageFig. 7 with image from de Preux Charles et al., 2016
Ab1-mcm5 surgical manipulation: pericardial cavity Fig. 1 with imageFig. 7 with imageFig. 8 with image from de Preux Charles et al., 2016
Ab-S46 standard conditions 11 figures with image from 9 publications
Ab1-mcm5 chemical treatment by injection: lipopolysaccharide Fig. 4 with image from de Preux Charles et al., 2016
Ab-S46 heat shock Fig. 4 with image from Rydeen et al., 2016
zn-5 chemical treatment: pharmaceutical Fig. 2Fig. 3Fig. 5Fig. 6 from Andersen et al., 2015
Ab2-kita kita standard conditions Fig. 2 from Verduci et al., 2014
PHENOTYPE
Phenotype in f2Tg
Phenotype Conditions Figures
atrium has extra parts of type cardiac muscle cell, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from D'Aniello et al., 2013
atrium cardiac muscle cell amount, normal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
atrium cardiac muscle cell decreased amount, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
atrium cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinoic acid Fig. 8 with image from D'Aniello et al., 2015
atrium cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinal Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell apoptotic, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinal Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinoic acid Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell decreased volume, abnormal chemical treatment: pharmaceutical Fig. 6 from Andersen et al., 2015
cardiac muscle cell decreased volume, abnormal chemical treatment: pharmaceutical Fig. 3 from Andersen et al., 2015
cardiac muscle cell decreased volume, abnormal chemical treatment: pharmaceutical Fig. 6 from Andersen et al., 2015
cardiac muscle cell increased volume, abnormal chemical treatment: pharmaceutical Fig. 5 from Andersen et al., 2015
cardiac muscle cell increased volume, abnormal chemical treatment: pharmaceutical Fig. 5 from Andersen et al., 2015
cardiac muscle cell apoptotic process increased process quality, abnormal hypoxia Fig. 5 with image from Parente et al., 2013
cardiac muscle cell cell death increased process quality, abnormal hypoxia Fig. 6 with image from Parente et al., 2013
cardiac muscle cell cell population proliferation increased process quality, abnormal hypoxia Fig. 7 with imageFig. 8 with image from Parente et al., 2013
cardiac muscle cell re-entry into mitotic cell cycle increased occurrence, abnormal surgical manipulation: pericardial cavity Fig. 1 with image from de Preux Charles et al., 2016
cardiac ventricle has extra parts of type cardiac muscle cell, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from D'Aniello et al., 2013
cardiac ventricle has normal numbers of parts of type cardiac muscle cell, normal chemical treatment by environment: 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE Fig. 5 with image from Rydeen et al., 2016
cardiac ventricle morphology, abnormal chemical treatment: pharmaceutical Fig. 3 from Andersen et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinoic acid Fig. 8 with image from D'Aniello et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinal Fig. 8 with image from D'Aniello et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
compact layer of ventricle tissue remodeling increased occurrence, abnormal chemical treatment by injection: (1->3)-beta-D-glucan Fig. 4 with image from de Preux Charles et al., 2016
heart has extra parts of type cardiac muscle cell, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from D'Aniello et al., 2013
heart linear, abnormal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
heart cardiac muscle cell proliferation increased occurrence, abnormal surgical manipulation: pericardial cavity Fig. 1 with image from de Preux Charles et al., 2016
heart tissue remodeling increased occurrence, abnormal surgical manipulation: pericardial cavity Fig. 3 with image from de Preux Charles et al., 2016
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 6 from Andersen et al., 2015
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 5 from Andersen et al., 2015
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 2Fig. 5 from Andersen et al., 2015
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 3 from Andersen et al., 2015

CITATIONS  (76)